PET imaging of TREM2 in amyloid-beta induced neuroinflammation
European Journal of Nuclear Medicine and Molecular Imaging · 2025
DOI: 10.1007/s00259-025-07358-0 ↗Kurz gefasst
Fachartikel in der Zeitschrift European Journal of Nuclear Medicine and Molecular Imaging, 2025. Verfasst von Amelia D Dahlén und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Public Health and Caring Sciences, Section of Molecular Geriatrics, Uppsala University, Uppsala, Sweden. Hauptthemen laut MEDLINE: Positron-Emission Tomography, Membrane Glycoproteins, Receptors, Immunologic, Amyloid beta-Peptides. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 52 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Uppsala University.
Abstract (Originalsprache)
Purpose
The triggering receptor expressed on myeloid cells 2 (TREM2) has become a promising target for biologics in both monitoring and treating neuroinflammation in Alzheimer’s disease (AD). This study aimed to develop and compare bispecific anti-TREM2 antibodies featuring different transferrin receptor (TfR) binders to enhance brain delivery, identifying the most suitable format for in vivo PET imaging of TREM2 in transgenic AD mice.
Methods
Three bispecific TREM2-antibody formats were produced and evaluated for their ability to cross the blood-brain barrier (BBB) via TfR-mediated transcytosis and bind TREM2. Blood concentration profiles up to 72 h post-injection (p.i.), and ex vivo brain uptake of iodine-125-labeled antibody constructs were quantified in App NL−G−F and age-matched wild type (WT) mice using a γ-counter. The best-performing bispecific TREM2-antibody was radiolabeled with iodine-124 and used for in vivo PET imaging of brain TREM2 levels in App NL−G−F mice at 72 h p.i. Brain TREM2 concentrations were subsequently quantified using ELISA.
Results
The antibody format carrying two scFv8D3 TfR-binders (IgG-scFv 2 ), demonstrated the highest brain concentrations of all tested bispecific constructs. This antibody also exhibited significantly higher brain concentrations in App NL−G−F mice compared to WT mice at both 48 and 72 h p.i. This difference was further visualized and quantified through in vivo PET imaging. Moreover, brain concentrations of the antibody ligand correlated with elevated TREM2 levels in brain homogenates.
Conclusion
These findings highlight IgG-scFv 2 as a promising radioligand for in vivo PET imaging of TREM2, advancing non-invasive neuroinflammation studies and supporting drug development for AD and other neurodegenerative diseases.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Public Health and Caring Sciences, Section of Molecular Geriatrics, Uppsala University, Uppsala, Sweden.
- Department of Public Health and Caring Sciences, Section of Molecular Geriatrics, Uppsala University, Uppsala, Sweden. stina.syvanen@uu.se.
ORCID-Profile: Amelia D Dahlén, Sahar Roshanbin, Ximena Aguilar, Nadja M Bucher, Sara Lopes van den Broek, Dag Sehlin, Stina Syvänen
Förderung
- Uppsala University
Zitieren
APA
Dahlén, A. D., Roshanbin, S., Aguilar, X., Bucher, N. M., Lopes van den Broek, S., Sehlin, D., & Syvänen, S. (2025). PET imaging of TREM2 in amyloid-beta induced neuroinflammation. European Journal of Nuclear Medicine and Molecular Imaging. https://doi.org/10.1007/s00259-025-07358-0
Vancouver
Dahlén AD, Roshanbin S, Aguilar X, Bucher NM, Lopes van den Broek S, Sehlin D, et al. PET imaging of TREM2 in amyloid-beta induced neuroinflammation. European Journal of Nuclear Medicine and Molecular Imaging. 2025. doi:10.1007/s00259-025-07358-0
BibTeX
@article{Dahln2025,
author = {Dahlén, Amelia D and Roshanbin, Sahar and Aguilar, Ximena and Bucher, Nadja M and Lopes van den Broek, Sara and Sehlin, Dag and Syvänen, Stina},
title = {PET imaging of TREM2 in amyloid-beta induced neuroinflammation},
journal = {European Journal of Nuclear Medicine and Molecular Imaging},
year = {2025},
doi = {10.1007/s00259-025-07358-0}
}
EUVIMED